Regeneus CEO Leo Lee with Proactive at the ASX Small and Mid-Cap Conference 2020

Regeneus CEO Leo Lee speaks to Proactive Investors' Andrew Scott while at the virtual ASX Small and Mid-Cap Conference 2020. During the interview, Leo talks about how Regeneus is working towards its mission to improve the quality of life for patients suffering from pain through their regenerative medicine products Progenza and Sygenus, the recent deal with Japanese manufacturing giant Kyocera Corporation, the experience of Regeneus' Board, and the current opportunity for investors.

Watch Leo's full interview with Proactive Investors here.


Mesenchymal Stem Cells: The Next Generation of Pain Treatments

Regeneus CEO Leo Lee is featured in the October 2020 edition of the European Pharmaceutical Review, writing on the field of regenerative medicine and its potential to dramatically transform the way that pain is treated.

Read Leo's full article in the European Pharmaceutical Review October 2020 digital edition here.


Regeneus featured in Morgans ‘Under The Microscope’ podcast

Morgans analyst Iain Wilkie sat down with Regeneus CEO Leo Lee to talk about the company's recent collaboration and licensing deal for Progenza OA for knee osteoarthritis in Japan and what it means for the company.

Listen to the podcast here.


Dr Boreham's Crucible: Regeneus is now riding the stem cell rollercoaster upwards

Business and life sciences writer Tim Boreham recently featured Regeneus in his regular biotech stocks column, Dr Boreham’s Crucible.

The column, published on Stockhead, reported that Regeneus' deal with Kyocera was important as it provided a clear commercialisation pathway for the lead stem cell platform technology Progenza.

Read the full article via Stockhead here.


Aussie stem cell company Regeneus out-licenses Progenza to Kyocera for Japan market

Biotechnology and biopharmaceutical industry publication, BioWorld, also covered the news on Regeneus out-licensing its lead mesenchymal stem cell (MSC) and Secretome therapy, Progenza, to Japan’s Kyocera Corporation for osteoarthritis of the knee for the Japan market, The report noted Kyocera has a strong presence among, and relationships with, physicians who treat osteoarthritis, and that this would help Progenza in the long term.

Read the full article here.


Regeneus, Kyocera ink $19M deal for knee osteoarthritis treatment

Bio and Health Sciences publication BioSpectrum covered Regeneus' deal with Kyocera for Progenza OA in Japan in their Asia Edition.

Read the full article in BioSpectrum Asia here.


Regeneus (ASX:RGS) Announces Collaboration With Kyocera

Regeneus CEO Leo Lee caught up with Finance News Network to talk about the company's collaboration with Japan's Kyocera Corporation to licence, manufacture and commercialise its stem cell therapy treatment Progenza.

Watch Leo's interview via The West Australian here


Regeneus CEO Leo Lee interviewed on ausbiz

Regeneus CEO Leo Lee was interviewed by Australian business, markets, startups news outlet, ausbiz, on Tuesday 11 August following the announcement that Regeneus had signed a new collaboration and licensing agreement with Kyocera for Progenza OA in Japan. In the interview, Leo noted the upfront and milestones payments were worth $27M, and that Regeneus would also receive royalties on product sales.

In the interview, Leo also noted that there were more than 25M potential patients with osteoarthritis in Japan, and that the number of people receiving treatment is rising each year.

Watch Leo's interview here.


Regeneus and Kyocera ink lucrative deal to commercialise Progenza in $3.5 billion dollar market

Financial news outlet finfeed featured Regeneus' Kyocera deal on the day of the announcement, offering in depth analysis of the company, the progress made so far in addressing the global pain market through its differentiated technologies, and the upcoming milestones investors can look forward to.

Read the full article via finfeed here.


Regeneus receives milestone payment from Kyocera

Australian biotechnology and life sciences online news source, BiotechDaily, reported that Regeneus received a non-refundable milestone payment of approximately $1.6 million (100 million Japanese Yen) from Kyocera Corporation as set out in the non-binding Memorandum of Understanding (MOU) signed on 2 March 2020.

Read the full article here.


Regeneus inks agreement with high profile Japanese life sciences group

Online investment publication Finfeed reported that Regeneus signed a non-binding memorandum of understanding (MOU) with Kyocera Corporation (Kyocera, TYO:6971), a diversified Japanese-based manufacturer with a strong position in the life sciences industry.

Read the full article here.


Regeneus (ASX:RGS) signs MOU with Kyocera for Progenza

The Market Herald - a leading source of authoritative breaking stock market news for self-directed investors - published an article reporting on Regeneus signing a non-binding memorandum of understanding with Kyocera Corporation.

Read the full article here.


ASX:RGS - Regeneus AGC Agreement termination paves way for commercial partner

Regeneus’ CEO Leo Lee spoke with Boardroom Media to discuss the recent termination of our AGC agreement and what it means for potential partners for our lead candidate, Progenza OA in Japan.

Listen to the full interview via Boardroom Media


Dr Boreham’s Crucible: Regeneus has pain sorted; now for long-term gain

Flush with fresh funding, the stem cell play’s overhauled management is supremely confident of striking a partnering deal in Japan pertaining to its lead osteoarthritis treatment Progenza.

This confident assertion - accompanied by a $5.54 million capital raising - lifts a burden of guilt for your columnist, who late last year put the mozz on the company by describing its board - barely changed since the company’s listing in 2013 - as remarkably stable.

Read the full article via Stockhead here.


90 Seconds With...Dr Alan Dunton

Regeneus (ASX:RGS) is a leading pain management and clinical-stage regenerative medicine company.

In a bid to fast-track its push for global growth, the company recently appointed two experienced leaders in life sciences and biotechnology to its board, including Dr Dunton.

Dr Dunton is a pharmaceutical and biotechnology industry leader with over 35 years of experience in senior company leadership roles, spanning pharmaceutical research and development to private biotechnology companies focussed on prescriptive treatment and the commercialisation of over-the-counter drugs on a global scale.

Of the appointment, Regeneus CEO Leo Lee said: “Dr Dunton’s wealth of knowledge in commercialising drugs on a global scale places Regeneus in a strong position to create a huge uplift in value for shareholders.”

Stockhead spoke with Dr Dunton about his recent appointment and the potential of Regeneus’ cell therapy technology.

Watch Dr Dunton's full video interview with Stockhead here.


Positive promise of stem cell therapy

Regenerating every cell, tissue or organ in the body, curing genetic disorders and chronic diseases, alleviating pain and delaying the onset of ageing, these are the altruistic promises of stem cell therapy.

A key driver of the regenerative medicine market, stem cell therapy’s infinite applications have biotechs racing to the clinical trial finishing line. More than 600 stem cell patents have been filed within Australia in the last five years and over 500 companies globally are involved in stem cell product development.

Read the full article in The Australian Financial Review here.


Regeneus prepares for global growth with appointment of life sciences industry leaders

ASX listed regenerative medicine company Regeneus (ASX: RGS) has today announced the appointments of John Chiplin, PhD and Alan W. Dunton, M.D. to its board of directors.

Joining Regeneus as Non-Executive Directors, both Chiplin and Dunton bring significant experience in leading and growing large-scale life sciences and biotechnology companies internationally.

The appointments come at a time when Regeneus is seeking to roll out its global growth strategy targeting the global pain market.

Read the full article published bu Star Investing here.


90 Seconds With...Leo Lee

Regeneus (ASX:RGS) announced this week that Dr John Chiplin, PhD and Dr Alan Dunton, M.D. have joined its board to support the company’s global growth strategy.

Dr Chiplin is Managing Director of Newstar Ventures and has significant operational, investment and transactions experienced in the international life science and technology industries.

Previously, he’s served as CEO at three publicly-listed software, biotechnology and cancer immunotherapy companies.

Dr Dunton is a senior pharmaceutical and biotechnology industry leader with experience across large pharmaceutical research and development organisations as well as private biotech companies focused on prescriptive treatment and the development and commercialisation of over-the-counter drugs on a global and local scale.

Regeneus’ CEO Leo Lee spoke with Stockhead about the potential impact of the new appointments.

Watch Leo's full video interview with Stockhead here.


Regeneus ramps up global focus with addition of industry leaders

Regeneus Ltd (ASX: RGS), a leading pain management and clinical-stage regenerative medicine company, has fast-tracked its push for global growth following the appointments of two highly successful leaders in life sciences and biotechnology to its board.

Read the full article on Stockhead here.


Regeneus' newly-appointed CEO Leo Lee discusses strategic plans for growth

Leo Lee, the newly-appointed CEO of Regeneus Ltd (ASX:RGS), speaks to Proactive Investors about the Australian clinical-stage regenerative medicine company's operations, and the wider scientific field.

The company holds a number of patents, and is focusing on global expansion, as it advances treatments in the areas of osteoarthritis, cancer, and dermatology.

Watch Leo's full interview with Proactive Investors here.